I already hold a couple of riskier smallcap biotechs, $CMPS and $ATAI , so I decided to move into this midcap commercial biotech I stumbled across for a bit more stability in my port, $EXEL . Already profitable and growing revenues, but also has multiple things in the pipeline. The cherry on top is zero debt on the balance sheets!
204 views
3 Comments
Ridge Capital@ridge_capital · 15d
I am already up +40% in $EXEL. Its metrics are absolutely impressive in my opinion, and they are aggressively executing buybacks. The main risk is that the company only has one product, so I am keeping an eye on the FDA decisions about its new products before the end of 2026. Feel free to take a look at the rest of my portfolio and see if you find any other interesting companies.
